TCDA News and Press, Tricida Inc. From 05/10/22

SOUTH SAN FRANCISCO, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA) announced today financial results for the three months ended March 31, 2022 and provided an update on key initiatives. Business Update Tricida continued to execute on the conduct ...

SOUTH SAN FRANCISCO, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA) today announced that it will report its first quarter 2022 financial results after the close of market on Tuesday, May 10, 2022. Tricida will host a conference call and webcast at 4:30 pm Eastern...

The following slide deck was published by Tricida, Inc. in conjunction with this event. For further details see: Tricida (TCDA) Presents At 21st Annual Needham Virtual Healthcare Conference - Slideshow

Tricida, Inc. (TCDA) Q4 2021 Earnings Conference Call March 29, 2022, 04:30 PM ET Company Participants Jackie Cossmon - SVP, IR and Communications Gerrit Klaerner - Founder, CEO and President Geoff Parker - COO and CFO Conference Call Participants Jessica Fye - JPMorgan Phil Nadeau - Cowen Pr...

Tricida press release (NASDAQ:TCDA): Q4 GAAP EPS of -$0.92 misses by $0.24. As of December 31, 2021, cash, cash equivalents and investments were $150.6 million. For further details see: Tricida GAAP EPS of -$0.92 misses by $0.24

Webcast Today at 4:30 pm Eastern Time SOUTH SAN FRANCISCO, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA) announced today financial results for the three months and year ended December 31, 2021 and provided an update on key initiatives. Business...

SOUTH SAN FRANCISCO, Calif., March 16, 2022 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA) today announced that it will report its fourth quarter and year-end 2021 financial results after the close of market on Tuesday, March 29, 2022. Tricida will host a conference call and webcast ...

Tricida (NASDAQ:TCDA) provided an update on the anticipated date for top-line data from the VALOR-CKD trial based on the ongoing events in Ukraine. ~15% of the patients randomized in VALOR-CKD are from Ukraine. Given the uncertainty around future participation of Ukrainian subjects in the tri...

SOUTH SAN FRANCISCO, Calif., March 02, 2022 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer, a non-absorbed, orally-administered polymer designed to slow chronic...

SOUTH SAN FRANCISCO, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer, a non-absorbed, orally-administered polymer designed to slow chronic...